Literature DB >> 8617315

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.

S I Abrams1, S F Stanziale, S D Lunin, S Zaremba, J Schlom.   

Abstract

Mutant ras p21 proteins contain sequences which distinguish them from normal endogenous ras and, thus, may represent unique epitopes for T cell recognition of antigen bearing tumor cells. Here, we examined the capacity of a mutant K-ras 9-mer peptide to induce in vivo CD8+ cytotoxic T lymphocytes (CTL). The peptide chosen reflected positions 4-12 of the point-mutated sequence of the K-ras oncogene encoding the Gly to Val substitution at codon 12. The overall rationale for selecting this particular 9-mer sequence was threefold: the mutant peptide contained a putative major histocompatibility complex (MHC) class I consensus anchor motif for murine H-2Kd; specific binding to MHC class I may then create an immunogenic complex for the induction of anti-ras CD8+ CTL; and finally, the mutant sequence overlapped with a newly characterized anti-ras CD4+ T helper type 1 epitope, which may have implications for the coordination and activation of both anti-ras immune mechanisms against the same target cell antigenic determinant. A functional interaction with H-2Kd was demonstrated with the mutant ras4-12(V12) peptide, but not the normal ras4-12(G12) peptide, which specifically inhibited an H-2Kd-restricted, anti-nucleoprotein NP147-155 CTL response in a dose-dependent fashion. An anti-ras CD8+ T cell line was then established from immune splenocytes of BALB/c (H-2d) mice injected with ras4-12 (V12) in adjuvant, which mediated peptide-specific lysis of syngeneic P815 tumor targets. Cytotoxicity was restricted by H-2Kd and strongly specific for the mutant ras peptide. Importantly, these anti-ras CTL specifically lysed a syngeneic tumor line (i.e. A20 lymphoma) transduced with the corresponding point-mutated ras oncogene, suggesting T cell receptor recognition of endogenously derived antigen. Overall, these data demonstrated that mutant ras p21 at codon 12(Gly-->Val) contained a peptide sequence which exhibited specific functional binding to a murine MHC class I molecule; the ability of the mutant, but not the normal sequence to bind selectively to murine MHC class I likely reflected the generation of a C-terminal anchor residue; and the ras4-12(V12) peptide was immunogenic for the production of antigen-specific CD8+ CTL, which lysed in vitro a syngeneic tumor cell line harboring the mutant K-ras oncogene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617315     DOI: 10.1002/eji.1830260225

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.

Authors:  Claudia Palena; Romaine I Fernando; Mary T Litzinger; Duane H Hamilton; Bruce Huang; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-03-22

2.  Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection.

Authors:  Mitra Bhattacharyya; Patrick Madden; Nathan Henning; Shana Gregory; Malika Aid; Amanda J Martinot; Dan H Barouch; Pablo Penaloza-MacMaster
Journal:  Immunology       Date:  2017-07-14       Impact factor: 7.397

3.  Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.

Authors:  P Escobar; Z Yu; A Terskikh; N Holmes; G Corradin; J P Mach; F Healy
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Detection and quantification of CD4(+) T cells with specificity for a new major histocompatibility complex class II-restricted influenza A virus matrix protein epitope in peripheral blood of influenza patients.

Authors:  T Linnemann; G Jung; P Walden
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  In vitro anti-tumor immune response induced by dendritic cells transfected with recombinant adenovirus carrying mutant K-ras genes.

Authors:  Feng Zhao; Qinghua Zhou; Yanrong Lu; Yang Qin; Jie Zhang; Jinsong Li; Jianjun Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

6.  Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection.

Authors:  Pablo Penaloza-MacMaster; Daniel L Barber; E John Wherry; Nicholas M Provine; Jeffrey E Teigler; Lily Parenteau; Stephen Blackmore; Erica N Borducchi; Rafael A Larocca; Kathleen B Yates; Hao Shen; W Nicholas Haining; Rami Sommerstein; Daniel D Pinschewer; Rafi Ahmed; Dan H Barouch
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

7.  K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia.

Authors:  Tomoyuki Okumura; Russell E Ericksen; Shigeo Takaishi; Sophie S W Wang; Zinaida Dubeykovskiy; Wataru Shibata; Kelly S Betz; Sureshkuma Muthupalani; Arlin B Rogers; James G Fox; Anil K Rustgi; Timothy C Wang
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

Review 8.  Vaccines against human carcinomas: strategies to improve antitumor immune responses.

Authors:  Claudia Palena; Jeffrey Schlom
Journal:  J Biomed Biotechnol       Date:  2010-03-16

9.  Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine.

Authors:  Jing Pan; Qi Zhang; Shizuko Sei; Robert H Shoemaker; Ronald A Lubet; Yian Wang; Ming You
Journal:  Oncotarget       Date:  2017-08-01

10.  Identification of the core regulators of the HLA I-peptide binding process.

Authors:  Yu-Hang Zhang; Zhihao Xing; Chenglin Liu; ShaoPeng Wang; Tao Huang; Yu-Dong Cai; Xiangyin Kong
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.